Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) Research & Development (2021 - 2025)

Medicinova (MNOV) has disclosed Research & Development for 7 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development changed N/A to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 million, a N/A change, with the full-year FY2025 number at $7.2 million, down 0.55% from a year prior.
  • Research & Development was $1.9 million for Q4 2025 at Medicinova, up from $1.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.6 million in Q2 2022 to a low of -$1.5 million in Q4 2023.
  • A 5-year average of $1.6 million and a median of $1.8 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 32.33% in 2023, then surged 133.97% in 2024.
  • Medicinova's Research & Development stood at $1.8 million in 2021, then soared by 44.34% to $2.6 million in 2022, then crashed by 157.44% to -$1.5 million in 2023, then surged by 226.21% to $1.9 million in 2024, then grew by 0.44% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Research & Development are $1.9 million (Q4 2025), $1.6 million (Q3 2025), and $1.8 million (Q1 2025).